Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / Intellikine, Inc.

2011 · Acquisition/Merger · $310M · Complete

Announcement Sentiment

Positive

Takeda America Holdings agreed to acquire Intellikine for $190M upfront plus up to $120M in milestones (~$310M total). Deal added two novel oncology kinase programs to the Millennium oncology pipeline. Closed Q1 2012.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Stalled

Assessment window: 10yr post-close.

Key facts

Announced Dec 12, 2011
Closed Jan 19, 2012
Deal value $310M
Deal type Acquisition/Merger
Therapeutic area Solid tumors, hematologic malignancies
Indications Solid tumors, hematologic malignancies
Key assets INK1117 (PI3K-alpha selective); INK128 (mTOR-C1/C2)
Mechanism PI3K-alpha selective and dual mTORC1/mTORC2 kinase inhibitors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals